Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Galmed Pharmaceutica (GLMD)

6 0.04 (0.67%)

05-24 16:00

Open:

5.971

Pre. Close:

5.96

High:

6.05

Low:

5.95

Volume:

34,428

Market Cap:

93M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

6.064 - 6.104

6.104 - 6.141

Low:

5.85 - 5.901

5.901 - 5.948

Close:

5.921 - 6.002

6.002 - 6.075

Technical analysis  (as of: 2018-05-24 5:28:17 PM)

Overall:

      

Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 7.50     One year: 8.76

Support:

Support1: 5.76    Support2: 5.36

Resistance:

Resistance1: 6.42    Resistance2: 7.50

Pivot:

6.04

Moving Averages:

MA(5): 6.04     MA(20): 6.03

MA(100): 7.30     MA(250): 7.47

MACD:

MACD(12,26): -0.02     Signal(12,26,9): -0.02

%K %D:

%K(14,3): 59.80     %D(3): 63.14

RSI:

RSI(14): 47.66

52-Week:

High: 12.22  Low: 3.61  Change(%): 18.3

Average Vol(K):

3-Month: 3768  10-Days 4081

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
GLMD has closed above bottom band by 41.9%. Bollinger Bands are 78.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to GLMD's normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2018-05-11T16:22:06-04:00
Galmed Pharmaceuticals' (GLMD) CEO Allen Baharaff on Q1 2018 Results - Earnings Call Transcript

2018-05-09T07:07:26-04:00
Galmed beats by $0.07, misses on revenue

2018-05-09T07:00:00-04:00
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results

2018-05-02T10:47:42-04:00
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH

2018-05-01T08:00:00-04:00
Galmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday, May 9

2018-04-27T15:34:12-04:00
Key events next week - healthcare

2018-04-16T07:00:00-04:00
Galmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol(TM) for NASH

2018-04-04T08:00:00-04:00
Your Daily Pharma Scoop: Geron Update, Rigel Setback, Bio-Path Results

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

14.47

Shares Float (M)

14.47

% Held by Insiders

% Held by Institutions

20.10

Shares Short (K)

48

Shares Short Prior Month (K)

35

Stock Financials

EPS

-0.890

EPS Est. Current Year

-0.940

EPS Est. Next Year

-0.960

EPS Est. Next Quarter

-0.250

Forward EPS

-0.990

Book Value (p.s.)

5.420

PEG Ratio

Profit Margin

Operating Margin

-1139.54

Return on Assets (ttm)

-68.2

Return on Equity (ttm)

-91.5

Qtrly Rev. Growth

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.369

Qtrly Earnings Growth

Operating Cash Flow (M)

-12.07

Levered Free Cash Flow (M)

-6.71

atoplab.com

Valuation

P/E

-6.74

P/E Growth Ratio

0.01

P/BV

1.11

P/S

1029333312.00

P/CF

-7.19

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.